Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AZN | NASDAQ | USD | Real-time | |
AZNl | BATS Europe | GBP | Delayed | |
AZNs | BATS Europe | SEK | Delayed | |
AZNCF | OTC Markets | USD | Delayed | |
3LAZ | London | GBP | Real-time | |
AZN | London | GBP | Real-time | |
3SAZ | London | GBP | Real-time | |
AZNN | Mexico | MXN | Delayed | |
AZNN | BIVA | MXN | Delayed | |
AZN | Stockholm | SEK | Real-time | |
AZN | Xetra | EUR | Delayed | |
AZN | Frankfurt | EUR | Delayed | |
AZN | TradeGate | EUR | Delayed | |
AZNPy | Frankfurt | EUR | Delayed | |
AZNPy | TradeGate | EUR | Delayed | |
AZN | Buenos Aires | ARS | Delayed | |
AZNA | Vienna | EUR | Real-time |
Novo Nordisk's revenues grew 31% in 2023, driven by the success of the anti-obesity drug Wegovy. As the Danish pharma giant eyes the top spot in the pharmaceutical industry, its stock faces...
AstraZeneca gained 8.95% in the past month, fueled by optimism about its 2024 earnings outlook. Rising sales of cancer and diabetes drugs are key contributors to AstraZeneca's positive...
Mega-cap stocks have been a favorite for long-term investors, providing stability, global reach, and consistent dividends. Using InvestingPro, we have curated a list of the top 36 mega-cap stocks. Our...
Tomorrow, long-standing dividend companies will announce their earnings. Ahead of the earnings, Colgate-Palmolive stock is undergoing a consolidation Meanwhile, Proctor & Gamble stock faces...
USThe Fed is expected to resume raising rates at the July 26 FOMC meeting. Fed funds futures see a 96% chance that the central bank will deliver a quarter-point rate rise, bringing the target range to...
(Wednesday market open) Investors seeking distraction from the ticking debt ceiling countdown clock get some this afternoon in the form of Federal Reserve meeting minutes and Nvidia (NASDAQ:NVDA)...
This market has reached a once-in-two-year turning point. And it’s made our favorite income investments—closed-end funds (CEFs)—terrific contrarian buys.That’s because the best...
Genome sequencing solutions company Illumina (NASDAQ:ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused shares to spiral down (-49%) for the...
Cost of sequencing a single human genome has fallen from $100 million to $600 since 2001 Illumina’s new machines can further drop the cost to under $200 Illumina won an antitrust lawsuit with...
Fed's expected aggressive tightening to contain soaring inflation, has many worrying about a possible recession. Three companies to protect your portfolio due to strong fundamentals, attractive...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review